Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04614090
Other study ID # Leif Mattisson
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2017
Est. completion date June 26, 2018

Study information

Verified date October 2020
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A retrospective case-control study. To evaluate if early surgery within 24hours of troch or subtrochanteric hip fractures using intramedullary nailing is safe in patients on warfarin treatment after fast reversal of the warfarin effect


Recruitment information / eligibility

Status Completed
Enrollment 198
Est. completion date June 26, 2018
Est. primary completion date February 1, 2018
Accepts healthy volunteers
Gender All
Age group 60 Years and older
Eligibility Exclusion Criteria: - Pathological fracture - Late presentation to the hospital - Other injuries

Study Design


Locations

Country Name City State
Sweden Södersjukhuset Stockholm Sjukhusbacken 10

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet Stockholm South General Hospital

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Mattisson L, Lapidus LJ, Enocson A. Is fast reversal and early surgery (within 24 h) in patients on warfarin medication with trochanteric hip fractures safe? A case-control study. BMC Musculoskelet Disord. 2018 Jun 26;19(1):203. doi: 10.1186/s12891-018-21 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Transfusion rates Hb value (g/dl) Pre-surgery
Primary Transfusion rates Transfusion rate (n) Pre-surgery
Primary Transfusion rates Hb value (g/dl) During the surgery
Primary Transfusion rates Transfusion rate (n) During the surgery
Primary Transfusion rates Hb value (g/dl) 2-4 days after the surgery
Primary Transfusion rates Transfusion rate (n) 2-4 days after the surgery
Primary adverse events Number of patients with a myocardial infarction, stroke, pulmonary embolism, deep venous thrombosis, sepsis, pneumonia, urinary tract infection, pressure ulcer, or any adverse events. Immediately after the surgery
Primary mortality The number of deaths Immediately after the surgery
Primary mortality The number of deaths 30-days after the surgery
Primary mortality The number of deaths 1 year after the surgery